An interventional study of Access site in Valve Stenoses, Aortic, sponsored by The Alfred. Completed at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by The Alfred · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Aortic Valve Stenosis with a site in Australia — 10 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Australia.
Among the 35 studies in Aortic Valve Stenosis with a site in Australia, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2024, is one of 28 with no phase, and was the 30th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →10 of the 35 studies in Aortic Valve Stenosis with a site in Australia are open now. Recruiting first, the newest first:
EnCompass Technologies, Inc. · Sites in Australia, United States
Ages 21–90
World Health Research Inc. · Sites in Australia, Canada, Colombia and 5 more countries
Transverse Medical, Inc. · Sites in Australia
Ages 18+
Abbott Medical Devices · Sites in Australia, France, Germany and 8 more countries
Ages 18–100
Edwards Lifesciences · Sites in Australia, United States, Canada and 1 more country
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2024.
This study's enrollment of 542 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 358 across the 28 interventional studies, 1,032 across the 7 observational. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 35 have an industry lead sponsor. The 10 most frequent:
The Alfred is the lead sponsor of 47 studies on the registry; 4 are open to participants now.
The Alfred has 2 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06689839EnCompass Technologies, Inc.Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | 2026-12 |
| NCT06991517World Health Research Inc.A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm | 2026-12 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
| NCT05172960Edwards LifesciencesALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | 2027-07 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Aortic Valve Stenosis with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Transcatheter aortic valve implantation (TAVI) is a well-known safe and effective treatment for anatomically suitable patients with severe aortic stenosis (AS). Despite rapid improvements in TAVI technique and technology, vascular and bleeding complications from both primary and secondary access sites remain significant, with approximately 25% of access related complications thought to be related to secondary access. The transfemoral route remains the most common approach for primary access during TAVI due to proven safety and efficacy. Secondary access during TAVI, which is needed for angiographic guidance, has drawn little attention in randomised trials of TAVI. In coronary intervention, the radial approach is now preferred due to high quality evidence suggesting lower bleeding and vascular complications compared to the femoral approach. Whilst randomised control trials comparing radial vs femoral as secondary access are lacking in the TAVI setting, observational studies comparing the two secondary access routes have shown a lower risk of bleeding and vascular complications with radial compared to femoral access. A systematic review of all the major observational trials also suggests that radial access might reduce risk of bleeding, vascular complications, and even 30-day mortality, but these data are limited to observational trials and there are no randomised controlled data to confirm these findings. Accordingly, we aim to undertake a multicentre, randomised controlled trial among patients undergoing transfemoral TAVI to assess if radial secondary access is superior to femoral secondary access.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other: Access site
Other: Access site
The SAFER-TAVI trial is randomized study comparing secondary access via a transradial versus transfemoral approach among patients undergoing transfemoral TAVI for aortic valve disease. Secondary access is gained along with primary access at the commencement of the TAVI procedure and is used for aortography before and after valve deployment and for assessment of the primary femoral access site after closure to confirm haemostasis. For patients assigned to radial access, the radial sheath will be removed using a radial band at the end of the procedure. For patients assigned to femoral access, the puncture site will be obtained under ultrasound guidance and fluoroscopic landmark identification. Unless contraindicated, the use of vascular closure devices will be recommended for all femoral cases. The choice of closure device is at the discretion of the operator. Catheters used in the access groups will be 5 or 6 French size at the discretion of the operator.
All clinically relevant bleeding and all vascular complications
The composite of all clinically relevant bleeding (defined as Bleeding Academic Research Consortium \[BARC\] type ≥2) and vascular complications (Valve Academic Research Consortium \[VARC3\] criteria) at 30 days.
Time frame: 30 days
All clinically relevant bleeding (BARC ≥2), overall and by access site
Using BARC criteria
Time frame: 30 days
All vascular complications, overall and by access site
Using VARC-3 criteria
Time frame: 30 days
All-cause death
Using VARC-3 criteria
Time frame: 30 days
Stroke
Using VARC-3 criteria
Time frame: 30 days
Myocardial infarction
Using VARC-3 criteria
Time frame: 30 days
Major adverse cardiovascular events
The composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke
Time frame: 30 days
Length of stay post-procedure
Length of stay post-procedure measured in time (days) from procedure to discharge
Time frame: 30 days
Overall procedure duration
TAVI procedure duration measured in time (minutes)
Time frame: 1 day
Radiation dose
Radiation dose measured as air kerma in milligrays
Time frame: 1 day
Conversion rate to alternative vascular access site
Conversion rate to alternative vascular access site
Time frame: 30 days
Tertiary site utilised to treat vascular complication
Tertiary site utilised to treat vascular complication
Time frame: 30 days
Failure to perform angiogram of primary access site at completion of TAVI
Failure to perform angiogram of primary access site at completion of TAVI
Time frame: 1 day
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Yes if ethics is approved
Ran from Feb 2024 to primary completion in Jun 2026, 28 months.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 28 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Alfred